Archive for the 'Peritoneal (Abdominal Mesothelioma)' Category
Malignant peritoneal mesothelioma; cancer of the lining of the abdominal caviety.
December 4th, 2008. Cytoreductive surgery and continuous hyperthermic peritoneal perfusion in patients with mesothelioma and peritoneal carcinomatosis: hemodynamic, metabolic, and anesthetic considerations
0082) after completion of CHPP compared with patients with peritoneal carcinomatosis. We conclude that the transient hemodynamic and metabolic perturbations associated with cytoreductive surgery and CHPP with cisplatin can vary according to the primary diagnosis (mesothelioma versus peritoneal carcinomatosis) warranting this therapy.
December 2nd, 2008. Malignant peritoneal mesothelioma-Results from the International Expanded Access Program using pemetrexed alone or in combination with a platinum agent
Results: Response rates (95% CI) for PEM, PEM/CIS, and PEM/CARBO were 12.5% (3.5, 29.0), 20.0% (7.7, 38.6), and 24.1% (10.3, 43.5), respectively. Median survival for PEM was 10.3 months. One-year survival rates for PEM/CIS and PEM were 57.4% (95% CI: 10.3, 100) and 41.5% (95% CI: 4.6, 78.4), respectively, and were not available for PEM/CARBO. Anemia was the most common serious adverse event (6.4%). Neutropenia (34.6%) was the most frequent CTC grade 3 or 4 toxicity reported. Concluding statement: PEM with or without a platinum agent was both active and well tolerated in patients with peritoneal mesothelioma.
November 17th, 2008. Outcomes of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal mesothelioma: the Australian experience
Conclusion: CRS and HIPEC is a treatment option for peritoneal mesothelioma. Patients with epithelioid tumor who undergo complete cytoreduction may potentially benefit from this procedure.
November 15th, 2008. Ectopic decidual reaction mimicking peritoneal tubercles: a report of three cases
Histology revealed extensive decidualisation. To the best of our knowledge, this is the first report of ectopic decidua mimicking peritoneal tubercles.
November 11th, 2008. Novel and existing mutations in the tyrosine kinase domain of the epidermal growth factor receptor are predictors of optimal resectability in malignant peritoneal mesothelioma
With longer follow-up, mut+ may not only be predictive of survival but may represent a subset of patients whose disease may be responsive to TK-inhibitor therapy. Experiments confirming the activating properties of the novel mutations are warranted.
Posted in Chemotherapy, Determining Efficacy, EGFR, Full Archive, Intraperitoneal Chemotherapy, Peritoneal (Abdominal Mesothelioma), Surgery, Treatment, Tumor Debulking, Type of Assessment:, Type of Mesothelioma: | No Comments »
November 5th, 2008. Cytoreductive surgery and intraperitoneal chemotherapy for peritoneal mesothelioma
Conclusions: Cytoreductive surgery combined with intraperitoneal chemotherapy appears to be the optimal treatment for selected patients with peritoneal mesothelioma. Increased familiarity with this condition's presentation and natural history, and knowledge of available treatment options, will hopefully facilitate treatment of these patients and expedite speedy referral to appropriate treatment centres.
Posted in Chemotherapy, Determining Efficacy, Full Archive, Intraperitoneal Chemotherapy, Peritoneal (Abdominal Mesothelioma), Surgery, Survival, Treatment, Tumor Debulking, Type of Assessment:, Type of Mesothelioma: | No Comments »
October 23rd, 2008. Malignant abdominal mesothelioma: defining the role of surgery
Conclusion: Surgical extirpation of MAM may be associated with significantly improved survival. All patients with MAM should be evaluated for potential surgical resection.
October 9th, 2008. Peritoneal Mesothelioma
To date there have been no universally accepted treatments for MPM. Unless referred to a specialty center, patients are routinely treated with pemetrexed and cisplatin which has been shown to increase survival in pleural mesothelioma.
Posted in Chemotherapy, Cisplatin (Platinol ®), Determining Efficacy, Doxorubicin, Full Archive, Intraperitoneal Chemotherapy, Pemetrexed (Alimta), Peritoneal (Abdominal Mesothelioma), Surgery, Treatment, Trimodality Therapy, Tumor Debulking, Type of Assessment:, Type of Mesothelioma:, mitomycin-C | No Comments »
October 8th, 2008. Acute abdomen in an asbestos factory worker
We treated a man who had a primary peritoneal mesothelioma with an unusual presentation — an acute abdomen. We report this case and discuss the relevant literature.
September 30th, 2008. Mesothelial reaction in longstanding Crohn’s ileitis simulating papillary mesothelioma
The peritoneal surface of the ileal resection specimen displayed exuberant tubulo-papillary formations of the mesothelium, with superficial invasion of the underlying stroma. The case demonstrates the well-recognised difficult differential diagnosis between a benign mesothelial proliferation and malignant mesothelioma in a novel clinical setting, and the diversity of the extramural manifestations of Crohn's disease.
September 27th, 2008. Treatment of peritoneal mesothelioma in pediatric patients
Treatment was well tolerated, and three of these patients have achieved long-term survival. The fathers of three of the patients worked in the construction industry and may have been the source of indirect asbestos exposure.
Posted in Case Study, Causation, Cisplatin (Platinol ®), Determining Efficacy, Full Archive, Occupational Asbestos Exposure, Peritoneal (Abdominal Mesothelioma), Survival, Treatment, Type of Assessment:, Type of Mesothelioma: | 2 Comments »
September 18th, 2008. Multicystic peritoneal mesothelioma is an uncommon lesion that is most often discovered incidentally
Abstract Symptoms are unusual. The lesion is benign with a favourable prognosis but local recurrence is reported not to be rare, and in a few cases malignant transformation has been described.
September 17th, 2008. Peritoneal Mesotheliomas: Clinicopathologic Features, CT Findings, and Differential Diagnosis
Conclusion: The clinicopathologic features of peritoneal mesotheliomas vary among the subtypes such as malignant mesotheliomas, cystic mesotheliomas, and well-differentiated papillary mesotheliomas, and accordingly, there is a spectrum of CT appearances.
September 17th, 2008. Metastasis of Malignant Peritoneal Epithelioid Mesothelioma in Endoscopic Gastric Biopsy: A Diagnostic Pitfall
Conclusions: Metastases of malignant peritoneal mesotheliomas are unusual, and a predominantly gastrointestinal localization is rare. Pathologists should be aware of this possibility to avoid misdiagnosis, particularly in small biopsy specimens.
September 16th, 2008. Survival of pleural malignant mesothelioma in Italy: a population-based study
Age and morphology were the main prognostic factors. Results regarding the effect of treatment were disappointing but may be useful to assess the future impact, at the population level, of recently introduced therapies.
September 16th, 2008. Survival of peritoneal malignant mesothelioma in Italy: a population-based study
Treatment was not associated with a statistically significant improvement in survival, but our study included cases first diagnosed before the introduction of the most recent therapeutic approaches. This provides a large historical comparison for future studies on survival trends at the population level.
August 30th, 2008. Technical aspects of cytoreductive surgery
The panel also agreed that in the closed technique for HIPEC administration the intestinal anastomoses should be fashioned after completion of the perfusion. Finally when considering the place for protective ostomies the experts voted for a flexible approach allowing the surgeon to exercise discretion for individual patients.
August 30th, 2008. Metastatic appendiceal mucinous adenocarcinoma to well-differentiated diffuse mesothelioma of the peritoneal cavity: a mimicker of florid mesothelial hyperplasia in association with neoplasms
Although commonly associated with atypical/ florid mesothelial hyperplasia, a carcinoma can rarely metastasize to a well-differentiated mesothelioma, which can pose significant diagnostic difficulties because it can mimic a reactive process. This unusual case report expands the spectrum of mesothelial proliferation in conjunction with a malignant neoplasm and serves to remind pathologists that such a concomitant occurrence exists.
August 19th, 2008. Rectus abdominis muscle resection for abdominal wall recurrence of mucinous adenocarcinoma or peritoneal mesothelioma
Conclusions: No patients required reoperation for abdominal wall hernia and mesh repair was not used in any of these patients. Disease control within the abdominal wall has been excellent.
|
|  |
